CINECA IRIS Institutional Research Information System

SCAGLIOTTI, Giorgio Vittorio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.030
AS - Asia 20.316
EU - Europa 18.353
SA - Sud America 981
OC - Oceania 548
AF - Africa 464
Continente sconosciuto - Info sul continente non disponibili 60
Totale 64.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.789
CN - Cina 12.365
IT - Italia 3.943
GB - Regno Unito 1.897
DE - Germania 1.853
IE - Irlanda 1.735
JP - Giappone 1.437
FR - Francia 1.391
SE - Svezia 1.271
KR - Corea 1.012
ES - Italia 963
IN - India 874
SG - Singapore 822
UA - Ucraina 794
CA - Canada 793
FI - Finlandia 721
TW - Taiwan 688
PL - Polonia 670
TR - Turchia 611
HK - Hong Kong 584
AT - Austria 582
VN - Vietnam 567
AU - Australia 482
BR - Brasile 450
NL - Olanda 448
MX - Messico 349
BE - Belgio 285
GR - Grecia 252
CH - Svizzera 244
DK - Danimarca 224
ID - Indonesia 195
RU - Federazione Russa 191
PT - Portogallo 180
IR - Iran 177
TH - Thailandia 177
RO - Romania 142
CO - Colombia 128
CL - Cile 118
EG - Egitto 117
IL - Israele 115
AR - Argentina 109
MY - Malesia 108
PE - Perù 102
PH - Filippine 92
NO - Norvegia 90
PK - Pakistan 90
ZA - Sudafrica 81
SA - Arabia Saudita 73
NZ - Nuova Zelanda 66
HU - Ungheria 65
CZ - Repubblica Ceca 64
HR - Croazia 62
RS - Serbia 58
MA - Marocco 57
EC - Ecuador 47
LB - Libano 44
EU - Europa 43
SI - Slovenia 41
NG - Nigeria 37
JO - Giordania 32
MO - Macao, regione amministrativa speciale della Cina 31
IQ - Iraq 30
SK - Slovacchia (Repubblica Slovacca) 28
SN - Senegal 28
BD - Bangladesh 27
TN - Tunisia 26
BA - Bosnia-Erzegovina 24
LT - Lituania 24
DZ - Algeria 23
AE - Emirati Arabi Uniti 22
EE - Estonia 22
PS - Palestinian Territory 20
BG - Bulgaria 19
CR - Costa Rica 17
PR - Porto Rico 17
SY - Repubblica araba siriana 17
AP - ???statistics.table.value.countryCode.AP??? 16
ET - Etiopia 16
KE - Kenya 16
LY - Libia 16
CY - Cipro 15
KZ - Kazakistan 15
MK - Macedonia 15
BY - Bielorussia 14
UZ - Uzbekistan 14
GT - Guatemala 12
GH - Ghana 11
LV - Lettonia 11
GE - Georgia 10
LK - Sri Lanka 9
QA - Qatar 9
VE - Venezuela 9
CU - Cuba 8
KG - Kirghizistan 8
NI - Nicaragua 8
RE - Reunion 8
AL - Albania 7
DO - Repubblica Dominicana 7
IS - Islanda 7
UY - Uruguay 7
Totale 64.640
Salva come PNG Salva come JPEG
Città #
Beijing 2.656
Chandler 1.720
Dublin 1.684
Houston 1.377
Fairfield 1.360
Shanghai 1.228
Redwood City 1.068
Ashburn 914
Torino 868
Wilmington 844
Woodbridge 726
Ann Arbor 707
Guangzhou 695
Nanjing 651
Seattle 633
Pisa 564
Cambridge 520
Medford 517
Jacksonville 499
Princeton 494
Vienna 490
Singapore 450
Villeurbanne 446
Taipei 443
Warsaw 407
Tokyo 400
Nyköping 383
Dearborn 365
Chengdu 350
Hangzhou 343
Zhengzhou 305
Wuhan 300
New York 291
Dong Ket 275
Fremont 274
Turin 260
Changsha 259
Jinan 257
London 257
Shenyang 223
Milan 221
Boston 215
Buffalo 194
Duncan 182
Los Angeles 172
Düsseldorf 171
Seoul 157
Hefei 156
Boardman 150
Nanchang 148
San Diego 147
Madrid 141
Toronto 141
Istanbul 137
Tianjin 136
Kunming 129
Central 128
Chongqing 126
Harbin 122
Osaka 120
Central District 119
Fuzhou 114
Chicago 112
Ottawa 112
Changchun 111
Xian 111
Barcelona 107
Rome 106
Hebei 96
Paris 94
Norwalk 86
Helsinki 83
Athens 81
Sydney 79
Jakarta 78
Brussels 77
Munich 77
Lima 76
Verona 73
Ankara 71
Santiago 70
Manchester 67
Hong Kong 64
Bangkok 62
Falls Church 61
Suzhou 61
Guiyang 59
Washington 59
Chennai 58
Seongnam 58
Hanoi 57
Philadelphia 57
Hyderabad 56
Lanzhou 56
Mumbai 56
Nanning 56
Amsterdam 55
Dallas 52
Delhi 52
Buenos Aires 51
Totale 32.626
Salva come PNG Salva come JPEG
Nome #
Lung cancer: current therapies and new targeted treatments 15.566
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer 2.590
A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer 1.285
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s 1.277
Papillary renal cell carcinoma: A review of the current therapeutic landscape 1.265
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. 1.185
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.159
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.154
Addressing the unmet need in lung cancer: The potential of immuno-oncology 1.014
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer 803
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 759
Novel anti-angiogenic therapeutic strategies in colorectal cancer 746
Hormonal treatment and quality of life of prostate cancer patients: new evidences 681
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? 649
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain 601
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. 584
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. 579
Extending survival of stage IV non-small cell lung cancer. 495
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 495
Enzalutamide in metastatic prostate cancer before chemotherapy. 488
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer 479
Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial 472
Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit 468
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 459
Apalutamide treatment and metastasis-free survival in prostate cancer 442
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1 383
Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. 359
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 335
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC 327
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. 323
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 315
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 309
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 295
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 281
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 270
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 263
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis 257
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report 257
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 247
First-line crizotinib versus chemotherapy in ALK-positive lung cancer 245
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 241
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 238
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 232
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker 229
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 223
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 221
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era 210
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 208
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 207
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 203
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. 200
Systemic recurrence of endometrial cancer more than 10 years after hysterectomy: a report of two cases and a brief review of the literature 198
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 192
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: A case report and review of the literature 192
The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. 191
Differentiation-inducing factor 1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and Thymidylate Synthase mRNAs accumulation 187
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines 185
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 184
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 174
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 170
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 168
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 163
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 162
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 161
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy 160
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 158
Novel investigational therapies for treating biliary tract carcinoma 153
Pros-IT CNR: an Italian prostate cancer monitoring project 147
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 145
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme. 145
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 145
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. 143
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 142
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 141
Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. 135
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. 131
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer 130
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 129
International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma 129
Current state-of-the-art therapy for advanced squamous cell lung cancer 129
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 128
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data 128
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials 127
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer 126
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 126
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. 123
Thymidylate synthase expression in large cell carcinoma ofthe lung 120
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. 120
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 113
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era 108
Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions 108
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 107
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer: A Phase-II Study. 107
Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions 107
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 106
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 106
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung 104
Diagnostica per immagini 103
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 103
Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2 102
Totale 49.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.006
article - articoli 0
book - libri 0
conference - conferenze 3.759
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.765
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.545 0 616 613 1.123 731 1.088 960 925 1.016 816 887 770
2020/202111.841 761 814 820 1.047 1.296 1.132 1.075 761 1.130 1.045 748 1.212
2021/20229.079 739 690 712 764 715 544 671 597 605 598 1.272 1.172
2022/20239.633 837 711 340 744 767 1.894 823 719 955 525 673 645
2023/20248.468 901 934 614 744 770 862 669 917 283 708 460 606
2024/2025333 268 65 0 0 0 0 0 0 0 0 0 0
Totale 67.077